Cancer Research AACR Legacy Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, J.
Right arrow Articles by Huang, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, J.
Right arrow Articles by Huang, C.
[Cancer Research 65, 6601-6611, August 1, 2005]
© 2005 American Association for Cancer Research

Molecular Biology, Pathobiology and Genetics

Loss of Tumor Suppressor p53 Decreases PTEN Expression and Enhances Signaling Pathways Leading to Activation of Activator Protein 1 and Nuclear Factor {kappa}B Induced by UV Radiation

Jian Wang1, Weiming Ouyang1, Jingxia Li1, Lixin Wei1,2, Qian Ma1, Zhuo Zhang1, Qiangsong Tong1, Jie He1,3 and Chuanshu Huang1

1 Nelson Institute of Environmental Medicine, School of Medicine, New York University, Tuxedo, New York; 2 Tumor Immunology and Gene Therapy Center, Eastern Hospital of Hepatobiliary Surgery, Second Military Medical University, Shanghai, China; and 3 Department of Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Requests for reprints: Chuanshu Huang, Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987. Phone: 845-731-3519; Fax: 845-351-2320; E-mail: chuanshu{at}env.med.nyu.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Transcription factor p53 and phosphatase PTEN are two tumor suppressors that play essential roles in suppression of carcinogenesis. However, the mechanisms by which p53 mediates anticancer activity and the relationship between p53 and PTEN are not well understood. In the present study, we found that pretreatment of mouse epidermal Cl41 cells with pifithrin-{alpha}, an inhibitor for p53-dependent transcriptional activation, resulted in a marked increase in UV-induced activation of activator protein 1 (AP-1) and nuclear factor {kappa}B (NF-{kappa}B). Consistent with activation of AP-1 and NF-{kappa}B, pifithrin-{alpha} was also able to enhance the UV-induced phosphorylation of c-Jun-NH2-kinases (JNK) and p38 kinase, whereas it did not show any effect on phosphorylation of extracellular signal-regulated kinases. Furthermore, the UV-induced signal activation, including phosphorylation of JNK, p38 kinase, Akt, and p70S6K, was significantly enhanced in p53-deficient cells (p53–/–), which can be reversed by p53 reconstitution. In addition, knockdown of p53 expression by its small interfering RNA also caused the elevation of AP-1 activation and Akt phosphorylation induced by UV radiation. These results show that p53 has a suppressive activity on the cell signaling pathways leading to activation of AP-1 and NF-{kappa}B in cell response to UV radiation. More importantly, deficiency of p53 expression resulted in a decrease in PTEN protein expression, suggesting that p53 plays a critical role in the regulation of PTEN expression. In addition, overexpression of wild-type PTEN resulted in inhibition of UV-induced AP-1 activity. Because PTEN is a well-known phosphatase involved in the regulation of phosphatidylinositol 3-kinase (PI-3K)/Akt signaling pathway, taken together with the evidence that PI-3K/Akt plays an important role in the activation of AP-1 and NF-{kappa}B during tumor development, we anticipate that inhibition of AP-1 and NF-{kappa}B by tumor suppressor p53 seems to be mediated via PTEN, which may be a novel mechanism involved in anticancer activity of p53 protein.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
It is well-known that UV radiation acts as both a tumor initiator and a tumor promoter, and plays major roles in the development of human nonmelanoma skin cancer (1). p53 is the most frequently mutated gene in human cancers and >90% of human nonmelanoma skin cancers harbor p53 mutation (2). During the process of photocarcinogenesis, UV-caused specific p53 mutations occur early in the keratinocytes (2). These mutations may result in the loss of the wild-type p53 function, and further UV exposure may lead to clonal expansion of p53-mutated keratinocytes and promotion of skin tumors (2). Therefore, p53 plays a critical role in the control of the immediate and adaptive responses to UV radiation and the onset of nonmelanoma skin cancer (2). Previous studies have also shown that p53 heterozygous mice show greatly increased susceptibility to skin cancer induction, and homozygous p53 knockout mice were even more susceptible (3). Accelerated tumor development in the heterozygotes was not associated with loss of the remaining wild-type allele of p53, as reported for tumors induced by some other carcinogens, but in many cases was associated with UV-induced mutations of p53 (3). All these reports support the idea that p53 plays a role in preventing the development of skin cancer induced by UV radiation.

The p53 tumor suppressor protein is a transcription factor that enhances the transcriptional rate of several genes involved in transducing signals from DNA damage (4–6). It is elevated in response to genotoxic agents, such as UV light, ionizing radiation, or certain chemicals (6). The activation of p53 has been implicated in cell cycle control, DNA repair, and apoptosis (7–9). The function of p53 is regulated at the levels of transcription, translation, protein modification and turnover, and cellular compartmentalization, as well as association with other proteins (10). However, the mechanisms by which p53 mediates anticancer activity is not completely understood although its activities in regulation of cell cycle and DNA repair, as well as apoptosis induction, are thought to participate in its anticancer activity (11–13). In the present study, we found that UV-induced signaling pathways related to activation of activator protein 1 (AP-1) and nuclear factor {kappa}B (NF-{kappa}B) were significantly increased in either the cells pretreated with a p53 inhibitor, pifithrin-{alpha}, or in the cells with p53 deficiency, suggesting that basal level of p53 normally has an inhibitory effect on signaling pathways leading to activation of AP-1 and NF-{kappa}B in cell response to UV radiation.

PTEN is a tumor suppressor that is a negative regulator of PI-3K/Akt pathway by dephosphorylation of the lipid second message, PI(3,4,5)P3, a product of phosphatidylinositol 3-kinase (PI-3K; ref. 14). PTEN has been shown to be involved in regulation of the cell apoptosis (15), cell cycle entry (16), cell proliferation (17), and cell adhesion (18). Although PTEN protein appears to be phosphoprotein in cells, its phosphorylation level is not regulated in cell response to extracellular stimuli (19). Thus, investigation of mechanisms involved in regulation of PTEN expression is a key step for understanding its tumor suppression function. In the studies presented here, we found that there is decreased PTEN protein expression in p53-deficient cells compared with that in p53 normally expressed cells. This may be the molecular basis by which p53 down-regulates signaling pathway leading to activation of AP-1 and NF-{kappa}B in cell response to UV radiation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents and plasmids. The p53-specific inhibitor pifithrin-{alpha}, p38 kinase inhibitor SB202190, and c-Jun-NH2-kinase (JNK) inhibitor II were purchased from Calbiochem (La Jolla, CA); luciferase assay substrate was obtained from Promega (Madison, WI); fetal bovine serum (FBS), Eagle's MEM, and DMEM were purchased from BioWhittaker (Walkersville, MD). Antibodies specifically targeting phospho- and total-PTEN, p53, Akt, p70S6k, and mitogen-activated protein kinase (MAPK) family members, including extracellular signal-regulated kinases (ERK), JNKs, and p38 kinase, were purchased from Cell Signaling Technology (Beverly, MA). Antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam (Cambridge, MA). AP-1–luciferase reporter (AP-1-Luc) containing seven tandem AP-1 binding sites (TGACTAA) and NF-{kappa}B–luciferase reporter (NF-{kappa}B-Luc) containing five tandem NF-{kappa}B binding sites (TGGGGACTTTCCGC) were purchased from Stratagene (La Jolla, CA). p53-luciferase is pG13 containing 13 tandem p53 binding sites as described previously (20, 21). Mouse p53 small interfering RNA (siRNA) construct was a generous gift from Dr. Michelle Craig Barton (Department of Biochemistry and Molecular Biology, University of Texas MD Anderson Cancer Center, Houston, TX) and described in his previously published studies (22). Enhanced green fluorescent protein (EGFP)-PTEN fusion protein expression plasmid was constructed as described previously (23) and was a gift from Dr. Xia Zhang (Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Saskatchewan, Canada).

Cell culture. The JB6 P+ mouse epidermal cell line Cl41 and its stable transfectants with various luciferase reporters (20, 21, 24, 25) were cultured in monolayers at 37°C under 5% CO2 using MEM containing 5% FBS, 2 mmol/L L-glutamine, and 25 µg/mL gentamicin. Normal embryonic fibroblasts (p53+/+) or p53-deficient embryonic fibroblasts (p53–/–), as well as their transfectants, were cultured in DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine, and 25 µg/ml gentamicin (21, 26). The cultures were dissociated with trypsin and transferred to new 75 cm2 culture flasks (Fisher, Pittsburgh, PA) from once to thrice per week.

Transfection. Cl41 cells were transfected with pAP-1-Luc plasmid alone or in combination with mouse p53 siRNA construct according to the LipofectAMINE 2000 reagent manual. Briefly, Cl41 cells were cultured in a six-well plate to 85% to 90% confluence. Five micrograms of plasmid DNA in combination with cytomegalovirus-neo vector for cotransfection, mixed with 10 µL of LipofectAMINE 2000 reagent, were used to transfect each well in the absence of serum. After 6 hours, the medium was replaced with 5% FBS MEM. Approximately 30 to 36 hours after the beginning of the transfection, the cells were digested with 0.033% trypsin and cell suspensions were plated onto 75 mL culture flasks and cultured for 24 to 28 days with G418 selection (400 µg/mL). Stable transfectant was established and cultured in G418-free DMEM for at least two passages before each experiment.

p53–/– fibroblasts were transiently transfected with AP-1-Luc, NF-{kappa}B-Luc alone, or in combination with either murine p53 expression plasmid or EGFP-PTEN fusion protein expression plasmid. The transfected cells were exposed to UV radiation for luciferase assay, Western Blot assay, or flow cytometry analysis 72 hours after the beginning of the transfection as described in the figure captions.

Activator protein 1 and nuclear factor-{kappa}B activity assay. Confluent monolayers of AP-1-Luc– or NF-{kappa}B-Luc–transfected cells were trypsinized, and 8 x 103 viable cells were added to each well of 96-well plates. Plates were incubated at 37°C in a humidified atmosphere of 5% CO2. After the cell density reached 80% to 90%, cells were treated as indicated in the figure captions. At different time periods after treatment, the cells were extracted with lysis buffer (Promega), and their luciferase activity was determined by the luciferase assay using a luminometer (Wallac 1420 Victor 2 multipliable counter system) after the addition of 50 µL of lysis buffer for 30 minutes at 4°C. The results are expressed as AP-1 or NF-{kappa}B activity relative to control medium (relative AP-1 or NF-{kappa}B activity; refs. 21, 26).

Assay for p53 activity. Confluent monolayers of Cl41 p53 mass1 cells were trypsinized, and 8 x 103 viable cells suspended in 100 µL of 5% FBS MEM were added to each well of 96-well plates. Plates were incubated at 37°C in a humidified atmosphere of 5% CO2. After the cell density reached 80% to 90%, cells were pretreated with pifithrin-{alpha} for 30 minutes at the concentrations indicated in the figure captions. The cells were then exposed to UVB or UVC radiation at doses indicated in the figure captions. At different time periods after treatment, the cells were extracted with lysis buffer (Promega) and their luciferase activity was determined by the luciferase assay using a luminometer (Wallac 1420 Victor 2 multipliable counter system) after the addition of 50 µL of lysis buffer for 30 minutes at 4°C. The results are expressed as p53 activity relative to control medium (relative p53 activity; refs. 20, 21).

Mitogen-activated protein kinase phosphorylation assay. Cl41 cells, normal embryonic fibroblasts (p53+/+), or p53-deficient embryonic fibroblasts (p53–/–), as well as their transfectants, were cultured in monolayers in six-well plates (26–28). After the cell density reached 70% to 80%, the cell culture medium was replaced with the medium supplemented with 0.1% FBS, 2 mmol/L L-glutamine, and 25 µg/ml of gentamicin per milliliter and cultured for 33 hours. Cells were incubated in serum-free medium for 3 to 4 hours at 37°C. Cells were exposed to UVB or UVC radiation at doses indicated in the figure captions. Cells were then extracted with Tris-glycine SDS sample buffer (Invitrogen, Carlsbad, CA). Western blots were done with either phosphospecific antibodies or pan antibodies against various kinases, including ERKs, JNKs, and p38 kinases. The protein band specifically bound to the primary antibody was detected using an anti-rabbit IgG-AP–linked and ECF Western blotting system (Amersham Biosciences, Piscataway, NJ; ref. 29).

Phosphorylation assay for Akt and p70S6k. Thirty thousand Cl41 cells, normal embryonic fibroblasts (p53+/+), or p53-deficient embryonic fibroblasts (p53–/–), as well as their transfectants, were cultured in each well of six-well plates to 70% to 80% confluence with normal culture medium (26–28). The cell culture medium was replaced with 0.1% FBS medium with 2 mmol/L L-glutamine and 25 µg/ml of gentamicin and cultured for 33 hours. Cells were incubated in serum-free medium for 3 to 4 hours at 37°C. Cells were exposed to UVB or UVC radiation at doses indicated in the figure captions. Cells were washed once with ice-cold PBS and extracted with SDS sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred, and probed with one of the antibodies, including rabbit phosphospecific Akt (Thr308) antibody, phosphospecific Akt (Ser473) antibody, pan Akt antibody, phosphospecific p70S6k (Thr389), phosphospecific p70S6k (Ser421/Ser424), and pan p70S6k antibody. The Akt and p70S6k protein bands specifically bound to primary antibodies were detected using an anti-rabbit IgG-AP–linked and ECF Western blotting system (30).

PTEN expression assay. Thirty thousand normal embryonic fibroblasts (p53+/+) or p53-deficient embryonic fibroblasts (p53–/–) were cultured in each well of six-well plates to 90% confluence with normal culture medium (27, 28). The cell culture medium was replaced with 0.1% FBS DMEM with 2 mmol/L L-glutamine and 25 µg/ml gentamicin and cultured for 33 hours. Cells were incubated in serum-free MEM for 3 to 4 hours at 37°C. Then, cells were exposed to UVB or UVC radiation at doses indicated in the figure captions. Cells were washed once with ice-cold PBS and extracted with SDS sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred, and probed with one of the antibodies, including rabbit phosphospecific PTEN (Ser380) antibody and PTEN antibody. The PTEN protein bands specifically bound to primary antibodies were detected using an anti-rabbit IgG-AP–linked and ECF Western blotting system.

Statistical analysis. The significance of the difference between treated and untreated groups were determined with the Student's t test. The results are expressed as mean ± SE.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Treatment of cells with pifithrin-{alpha} resulted in activation of activator protein 1 and nuclear factor-{kappa}B. AP-1 and NF-{kappa}B have served to detect one of the decisive DNA-binding motifs required for gene regulation by tumor promoters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and UV irradiation (31). Previous studies suggest that AP-1 plays a crucial role in tumor promoter–induced cell transformation (24). To investigate the potential role of p53 activation in the regulation of signaling pathways leading to activation of AP-1 and NF-{kappa}B in Cl41 cells, we first measured the effects of pifithrin-{alpha}, a p53 inhibitor that was discovered by Komarov et al. (32) and is now widely used as the inhibitor in p53 studies (33–35), on activation of AP-1 and NF-{kappa}B in mouse JB6 epidermal C141 cells. The results showed that pifithrin-{alpha} treatment alone was able to induce activation of AP-1 and NF-{kappa}B in Cl41 cells (Fig. 1A and B). The induction of AP-1 and NF-{kappa}B by pifithrin-{alpha} was observed in all time points tested (Fig. 1C). These results indicated that inhibition of p53 by pifithrin-{alpha} could result in activation of AP-1 and NF-{kappa}B in Cl41 cells, suggesting that normal p53 protein expression may function as an inhibitor in the regulation of basal level of AP-1 and NF-{kappa}B activity.



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Activation of AP-1 and NF-{kappa}B by pifithrin-{alpha} (PFT{alpha}) in Cl41 cells. Eight thousand P+1-1 or Cl41 NF-{kappa}B mass1 cells were seeded into each well of 96-well plates, and cultured in 5% FBS MEM at 37°C. After the cell density reached 80% to 90%, the cells were treated with 5 µmol/L pifithrin-{alpha}. After incubation for 24 hours (A and B) or at various time points as indicated (C), cells were extracted with lysis buffer, and luciferase activity was measured using Promega luciferase assay reagent with a luminometer after addition of 50 µL of lysis buffer for 30 minutes at 4°C. The results are expressed as AP-1 or NF-{kappa}B induction relative to control medium. Columns, mean of triplicate assay wells; bars, SD. *, significant increase from medium control (P < 0.05).

 
Inhibition of p53 led to increase in UV-induced activator protein 1 activities. Results from above studies suggested that p53 may provide an inhibitory signaling for AP-1 activation. If this is the case, the inhibition of AP-1 activation by p53 may be more significant in the Cl41 cells response to UV radiation. To carry out this investigation, both p53-luciferase reporter stable transfectant, Cl41 p53 mass1, and AP-1 luciferase reporter stable transfectant, P+1-1, were pretreated with pifithrin-{alpha} for 30 minutes and then exposed to UV radiation. Pretreatment of cells with pifithrin-{alpha} led to dramatic inhibition of UV-induced p53-dependent transactivation (Fig. 2A and B), whereas it markedly increased UV-induced AP-1 transactivation (Fig. 2B). Moreover, the inhibition of p53-dependent transactivation occurred before the increase in AP-1 transactivation (Fig. 2C). Because it has been reported that pifithrin-{alpha} is also able to inhibit heat shock and glucocorticoid receptor signaling (35), p53 siRNA was further used to address the causality between loss of p53 function and elevation of AP-1 activation. The results indicated that p53 siRNA can inhibit the expression of p53, which subsequently leads to the decrease in phosphorylation of p53 at Ser15 induced by UV radiation (Fig. 2D and E). More importantly, knockdown of p53 expression in Cl41 cells by its specific siRNA caused the elevation of UV-induced AP-1 activation (Fig. 2F). These results, together with the induction of AP-1 activity by pifithrin-{alpha} alone, indicate that p53 is able to not only inhibit basal level of AP-1 activity, but also exhibits a strong inhibition of UV-induced AP-1 activation, which may participate in the anticancer activity of p53 in cells exposed to carcinogenic factors, such as UV radiation.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Inhibition of p53-dependent transactivation by pifithrin-{alpha} or its siRNA led to increase in UV-induced AP-1 activity. Eight thousand C141 p53 mass1 or P+1-1 cells were seeded into each well of 96-well plates and cultured in 5% FBS MEM at 37°C. After the cell density reached 80% to 90%, the cells were first pretreated with various concentrations of pifithrin-{alpha} for 30 minutes, then exposed to UVB (2 kJ/m2) or UVC (60 J/m2) for p53 induction (A); the cells were first pretreated with 5 µmol/L pifithrin-{alpha} for 30 minutes, then exposed to UVC (60 J/m2) for AP-1 or p53 induction (B). After a 24-hour incubation, cells were extracted with lysis buffer, and luciferase activity was measured using Promega luciferase assay reagent with a luminometer after addition of 50 µL lysis buffer for 30 minutes at 4°C. C, the cells were treated as described in (B) and then extracted for luciferase assay at different time points as indicated. The results are expressed as p53 or AP-1 induction relative to control medium. Points, mean of triplicate assay wells; bars, SD. *, significant increase from UV radiation (P < 0.05); {clubsuit}, significant decrease from UV radiation (P < 0.05). D and E, Cl41 p53 siRNA transfectant (Cl41 sip53/AP-1-Luc) and its vector control transfectant (Cl41 AP-1-Luc) were exposed to UVB radiation at doses as indicated. After a 12-hour incubation, the cells were washed once with ice-cold PBS and extracted with the SDS sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred, and probed with antibody against p53 (D) or phosphorylated p53 (Ser15; E). The protein band specifically bound with primary antibodies was detected by using anti-rabbit IgG-AP–linked and ECF Western blotting system. F, Cl41 AP-1-Luc and Cl41 sip53/AP-1-Luc cells were exposed to UVB (2.0 kJ/m2) and then extracted with lysis buffer 24 hours after the UVB exposure. The luciferase activity was measured as described in Fig. 1. The results are expressed as AP-1 induction relative to control medium. *, significant increase from vector control transfection (P < 0.05).

 
p53-modulated, UV-induced activator protein 1 activation through upstream p38 kinase and c-Jun-NH2-kinases. Because our results indicated that inhibition of p53 transactivation by either pifithrin-{alpha} increased UV-induced AP-1 activation, it was important to know whether the increased AP-1 induction was due to p53 direct effect on AP-1 complex or AP-1 upstream kinase. Hence, we observed the effects of pifithrin-{alpha} on UV-induced activation of MAPKs family, including ERKs, JNKs, and p38 kinase, in C141 cells. As shown in Fig. 3, UVC radiation alone resulted in phosphorylation of JNKs and p38 kinase (Fig. 3), and pifithrin-{alpha} treatment resulted in marked enhancement of UV-induced phosphorylation of JNKs and p38 kinase, whereas it did not show any increased activation of ERKs and protein expression of these kinases (Fig. 3). Moreover, the elevation of AP-1 activity in p53 siRNA-transfected Cl41 cells was reversed by the treatment of cells with JNKs and p38 inhibitors (Fig. 3B). These results indicate that p53 might play an important role in the regulation of AP-1 upstream kinases, p38 kinase, and JNKs.



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Inhibition of p53 by pifithrin-{alpha} resulted in increased UV-induced p38 kinases and JNKs, but not ERKs. Thirty thousand Cl41 cells were seeded into each well of six-well plates, and cultured in 5% FBS MEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS MEM. Thirty-three hours later, cells were incubated in serum-free MEM for 3 to 4 hours at 37°C. Cells were first pretreated with various concentrations of pifithrin-{alpha} for 30 minutes and then exposed to UVC (30 J/m2). After a 60-minute incubation, cells were washed once with ice-cold PBS and extracted with a SDS sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred, and probed with either phosphospecific antibodies or pan antibodies against JNKs, p38 kinases, and ERKs. The protein band specifically bound with primary antibodies was detected by using anti-rabbit IgG-AP–linked and ECF Western blotting system. B, Cl41-sip53/AP-1-Luc cells were pretreated with 2 µmol/L SB202190 or 25 µmol/L JNK inhibitor II for 30 minutes. Then, Cl41-AP-1-Luc and the pretreated Cl41-sip53/AP-1-Luc cells were exposed to UVB (2 kJ/m2) for AP-1 induction. After a 12-hour incubation, cells were extracted with lysis buffer, and luciferase activity was measured as described in Fig. 1. The results are expressed as AP-1 induction relative to control medium. *, significant increase from vector control transfection (P < 0.05); {clubsuit}, significant decrease from medium control (P < 0.05).

 
Loss of p53 increased the phosphorylation of p38 kinase and c-Jun-NH2-kinase, but not extracellular signal-regulated kinases, in UV responses. To obtain direct evidence for the involvement of p53 in UV-induced AP-1 activation, we then compared UV-induced phosphorylation of MAPK family members, including JNKs, p38 kinase, and ERKs, between wild-type p53 (p53+/+) and p53-deficient (p53–/–) fibroblast cell lines derived from mouse embryos (27, 28). Very interestingly, the results from studies of UV-induced MAPK activation showed that UV-induced phosphorylation of JNKs and p38 kinase were increased significantly in p53–/– cells compared with those in p53+/+ cells (Figs. 4A and B), whereas it did not show any effect on phosphorylation of ERKs (Fig. 4C). These data suggest that p53 deficiency specifically leads to increase in activation of p38 kinase and JNKs, but not ERKs, compared with p53 wild-type cells in UV responses.



View larger version (49K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Loss of p53 protein expression led to increase in UV-induced MAPK activation. Thirty thousand p53+/+ or p53–/– embryonic fibroblasts were seeded into each well of six-well plates and cultured in 10% FBS DMEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS DMEM. Thirty-three hours later, cells were incubated in serum-free DMEM for 3 to 4 hours at 37°C, and then exposed to UVB (2 kJ/m2) and UVC (30 J/m2) radiation. After incubation at various time points as indicated, cells were washed once with ice-cold PBS and extracted with a SDS sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred, and probed with either phosphospecific antibodies or pan antibodies against p38 kinases (A), JNKs (B), and ERKs (C). The protein band specifically bound with primary antibodies was detected by using anti-rabbit IgG-AP–linked and ECF Western blotting system.

 
Loss of p53 function increased the phosphorylation of Akt and p70S6k induced by UV radiation. Because our recently published data show that UV radiation is able to induce phosphorylation of Akt and p70S6K in Cl41 cells (36) and Akt phosphorylation is a mediator for activation of AP-1 and JNKs in Cl41 cells response to benzo(a)pyrene diol epoxide [B(a)PDE] exposure (30), we further investigated the effects of pifithrin-{alpha} on UV-induced phosphorylation of Akt and p70S6k in Cl41 cells. The results showed that pretreatment of cells with pifithrin-{alpha} led to a significant increase in UV-induced phosphorylation of Akt at Ser473 and Thr308 and p70S6k at Thr389 and Thr421/Ser424 (Fig. 5A), indicating that an inhibition of p53 may lead to increase in the phosphorylation of Akt and p70S6k in mouse epidermal Cl41 cell response to UV radiation. To obtain a direct evidence for involvement of p53 in the regulation of Akt and p70S6k, we further compared UV-induced phosphorylation of Akt and p70S6k between wild-type p53 (p53+/+) and p53-deficient (p53–/–) cells (27, 28). As shown in Fig. 5B and C, deficiency of p53 function by knockout of p53 gene (p53–/–) significantly increased the phosphorylation of Akt at Ser473 and Thr308 and p70S6k at Thr389 and Thr421/Ser424 in cell response to UV radiation compared with those in wild-type p53 (p53+/+) cells. Furthermore, we also observed that inhibition of p53 with its specific siRNA enhanced UV-induced phosphorylation of Akt in Cl41 cells (Fig. 5D). Taken together with the evidence that activation of Akt and p70S6k plays an important role in tumor development (37), these results suggest that p53 protein expression may function as an inhibitor of signaling pathways involved in UV-induced carcinogenesis.



View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Effects of p53 on UV-induced phosphorylation of Akt and p70S6k. A, 3 x 104 Cl41 cells were seeded into each well of six-well plates, and cultured in 5% FBS MEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS MEM. Thirty-three hours later, cells were incubated in serum-free MEM for 3 to 4 hours at 37°C. Cells were first pretreated with pifithrin-{alpha} for 30 minutes and then exposed to UVB (1 kJ/m2) or UVC (15 J/m2). After a 60-minute incubation, cells were washed once with ice-cold PBS and extracted with a SDS sample buffer. Western blot was done with either phosphospecific antibodies or pan antibodies against Akt and p70S6k. The number below the bands indicates its relative quantity. B and C, 3 x 104 p53+/+ or p53–/– embryonic fibroblasts were seeded into each well of six-well plates, and cultured in 10% FBS DMEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS DMEM. Thirty-three hours later, cells were incubated in serum-free DMEM for 3 to 4 hours at 37°C, and then exposed to UVB (2 kJ/m2) and UVC (30 J/m2) radiation. After incubation at various time points as indicated, cells were washed once with ice-cold PBS and extracted with a SDS sample buffer. The cell extracts were used for Western blot and probed with either phosphospecific antibodies or pan antibodies against Akt and p70S6k. The protein band specifically bound with primary antibodies was detected by using anti-rabbit IgG-AP–linked and ECF Western blotting system. The number below the bands in (B) indicates its quantity relative to the medium control. D, Cl41 AP-1-Luc and Cl41 sip53/AP-1-Luc cells were seeded and treated as described above. Ninety minutes after exposure to UVB radiation, the cells were extracted and analyzed by Western blot with antibodies against Akt or phosphorylated Akt.

 
p53 reconstitution down-regulated UV-induced activator protein 1, nuclear factor-{kappa}B, Akt, and mitogen-activated protein kinase activation. To further confirm that the elevation of AP-1, NF-{kappa}B, Akt, and MAPK activation in p53–/– cells in UV response directly resulted from the deficiency of p53, we transfected wild-type mouse p53 back into p53–/– cells and then compared the activation of these signal pathways between p53–/– and p53–/– with wild-type p53 reconstitution cells after UV radiation. The results showed that reconstitution of p53 led to obvious decreases in AP-1 and NF-{kappa}B transcriptional activation, phosphorylation of Akt, JNKs, and p38 kinase (Fig. 6A-E). It may be notable that the difference in JNK phosphorylation between p53–/– and p53–/– with wild-type p53 reconstitution cells is not as obvious as that between p53–/– and wild-type fibroblasts. This may be explained by the fact that the reconstituted p53 expression in p53–/– cells is a constitutive overexpression, which acts in a different manner from that in wild-type cells. Overall, these data provide reliable evidence to support our notion that p53 deficiency could cause activation of Akt, p38 kinase, and JNKs.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Reconstitution of p53 down-regulated AP-1 and NF-{kappa}B transactivation and phosphorylation of p38 kinase, JNK, and Akt. p53–/– embryonic fibroblasts were transiently transfected with pAP-1-Luc and pNF-{kappa}B-Luc alone or in combination with mouse wild-type p53 expression vector as described in Materials and Methods. A, the transfected cells were extracted with the SDS sample buffer, and p53 expression was identified by Western blot with anti-p53 antibody. B and C, 1 x104 transfected cells were seeded into each well of 48-well plates, and cultured in 10% FBS DMEM at 37°C. After the cell density reached 80% to 90%, the cells were exposed to UVB (2 kJ/m2) radiation. After incubation for 12 hours, cells were extracted with lysis buffer, and luciferase activity was measured as described in Fig. 1. The results are expressed as AP-1 and NF-{kappa}B induction relative to control medium. Columns, mean of triplicate assay wells; bars, SD. *, significant decrease from mock transfections (P < 0.05). D and E, 3 x 104 p53–/– embryonic fibroblasts transiently transfected with mock vector or mouse p53 were seeded into each well of six-well plates and cultured in 10% FBS DMEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS DMEM. Thirty-three hours later, cells were incubated in serum-free DMEM for 3 hours at 37°C and then exposed to UVB (2 kJ/m2) radiation. After incubation for 60 minutes, cells were extracted with the SDS sample buffer and analyzed by Western blot with antibodies as indicated. GAPDH was used as a protein loading control.

 
p53 deficiency led to reduction of PTEN expression. Because previous studies indicated that PTEN was able to effectively antagonize PI-3K/Akt signaling pathway, it is reasonable for us to investigate the role of p53 in the regulation of PTEN expression in wild-type p53 (p53+/+) and p53-deficient (p53–/–) cell lines. As shown in Fig. 7A, UVB and UVC radiation resulted in no alteration of expression and phosphorylation of PTEN in p53 wild-type (p53+/+) cells. However, deficiency of p53 expression by p53 knockout significantly decreased the phosphorylated and total PTEN protein expression compared with those in p53+/+ cells (Fig. 7B), which is consistent with previous findings that p53 is an activator of PTEN transcription through a p53-responsive element within the PTEN promoter (38). Moreover, transfection of PTEN into p53–/– cells (Fig. 7C) also resulted in a decrease in AP-1 transactivation (Fig. 7D). Taken together with the above results that p53 deficiency increased the phosphorylation of Akt and p70S6k in the same cell culture models, and in view of the inhibitory effect of PTEN on phosphorylation of Akt and p70S6k (14), we anticipate that basal level of p53 expression may inhibit UV-induced activation of Akt and p70S6k by regulating the expression of PTEN protein.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 7. Loss of p53 caused the decrease in PTEN expression in embryonic fibroblast cells. Thirty thousand p53+/+ or p53–/– embryonic fibroblasts were seeded into each well of six-well plates, and cultured in 10% FBS DMEM at 37°C. After the cell density reached 70% to 80%, the cell culture medium was replaced with 0.1% FBS DMEM. Thirty-three hours later, cells were incubated in serum-free DMEM for 3 to 4 hours at 37°C, then exposed to UVB (2 kJ/m2) and UVC (30 J/m2) radiation (A), or without UV exposure (B). After incubation at various time points as indicated, cells were extracted with a SDS sample buffer. The cell extracts were used to carry out Western blot and probed with either phosphospecific or total antibodies against PTEN. The protein band specifically bound with primary antibodies was detected by using anti-rabbit IgG-AP–linked and ECF Western blotting system. C and D, p53–/– embryonic fibroblasts were transiently transfected with pAP-1-Luc alone or in combination with EGFP-PTEN expression vector as described in Materials and Methods. C, the expression of EGFP-PTEN was identified by FCM assay. Gray histograms, mock vector–transfected cells; black histograms, EGFP-PTEN–transfected cells. D, 2 x 104 transfected cells were seeded into each well of 48-well plates and cultured in 10% FBS DMEM at 37°C. After the cell density reached 80% to 90%, the cells were exposed to UVB (2 kJ/m2) radiation. After incubation for 12 hours, the cells were extracted with lysis buffer, and luciferase activity was measured as described in Fig. 1. The results are expressed as AP-1 induction relative to control medium. Columns, mean of triplicate assay wells; bars, SD. *, significant decrease from vector control transfection (P < 0.05).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Transcription factor p53 is one of the classic tumor suppressor genes that interfere with cancer development (39). Although molecular mechanisms involved in anticancer effects of p53 have attracted a great deal of attention in the last decades, many questions, specifically for the role of p53 in down-regulation of tumor promotion–related signaling pathways, are not well explored (40). The present studies show that the p53 protein functions as a down-regulator in both basal level of AP-1 activities and UV-induced level of AP-1 activities. This conclusion was based on the findings that the inhibition of normal p53 function by either p53 chemical inhibitor, knockdown of p53 expression with its specific siRNA, or knockout of p53 gene resulted in AP-1 activation and increased UV-induced AP-1 activities. We also found that inhibitory effects of p53 on AP-1 activation are due to its specific inhibition of the p38 kinase and JNK pathways, but not the ERK pathway. In addition, activation of Akt/p70S6k, an important signaling pathway required for tumor promotion, was also down-regulated by p53 because inhibition or knockout of p53 resulted in significant increases in phosphorylation of Akt at Ser473 and Thr308, and p70S6k at Thr389 and Thr421/Ser424. Furthermore, we found that the expression of PTEN, a tumor suppressor that is a negative regulator of PI-3K/Akt pathway, was decreased in p53-deficient embryonic fibroblast cell lines. All these data showed that anticancer activity of p53 is not only mediated by its regulation of DNA damage repair, growth arrest, and apoptosis, but also by its down-regulation of cancer promotion-associated signaling pathways.

p53 was first described as a cellular phosphorprotein that coprecipitated with the large T antigen of SV40, whose synthesis was enhanced in chemically transformed tumors (41). In the last 20 years, its role and the molecular mechanisms involved in p53 tumor suppression have attracted great attention. However, most of those studies focused on its regulation of DNA damage and its repair, cell cycle arrest, and apoptosis. It is known that p53 controls an essential growth checkpoint that protects against both genomic rearrangement and the accumulation of mutations caused by exposure of carcinogens (42). For example, UV radiation is able to activate p53 by induction of its protein expression, phosphorylation, and acetylation (42, 43). Once p53 is activated, it can lead to cell cycle arrest or apoptosis (i.e., damaged cells undergo DNA repair or severely damaged cells are discarded; ref. 42). The exact outcome of p53 induction may depend on the cell types and strength of the UV exposure. Because p53 is the most commonly (over 50%) mutated gene associated with human tumors, it seems to be localized at a central place that can receive signals via various pathways and control numerous downstream pathways (40, 44). Therefore, in addition to its important role in the control of cell cycle, apoptosis, and DNA repair, p53 may also affect the signaling pathways that are directly involved in cell growth and transformation. This hypothesis is indirectly supported by the previous findings that p53 can suppress cell transformation caused by oncogene activation (45). To address this issue, the present studies directly investigated the potential effects of p53 on basal level and UV-induced level of AP-1 and NF-{kappa}B activities. Our data shown here indicate that p53 inhibition leads to the induction of AP-1 and NF-{kappa}B, as well as the increase in UV-induced AP-1 activities. Because AP-1 and NF-{kappa}B are two key transcription factors that are required for tumor development, which has been well shown both in vitro and in vivo in previous studies (46, 47), we anticipate that p53 normally functions as an inhibitor of AP-1 and NF-{kappa}B signaling pathways to exert its anticancer activity.

Substantial contributions have been made to elucidate the signal transduction pathways involved in UV-induced activation of AP-1 and NF-{kappa}B. Of particular interest are the MAPK signal transduction pathways, including the ERKs, JNKs, and the p38 kinase, which control the activities of various transcription factors, including AP-1 and NF-{kappa}B (48). ERKs are activated and play a critical role in transmitting signals initiated by TPA and growth factors, such as epidermal growth factor and platelet-derived growth factor (48). JNKs and p38 kinases are potently activated by various forms of inflammatory signals or stress, including UV radiation (48). Recent studies indicate that wild-type p53 inhibits the activation of transcription factor Net, an effector of the Ras oncogene/MAPK pathway (49). Loss of p53 in vivo leads to an increase of Net phosphorylation in skin response to UV radiation (49). However, the exact effect of p53 on MAPK activation induced by UV radiation remains unclear. In this study, we found that inhibition or knockout of p53 resulted in an increase in the phosphorylation of JNKs and p38 kinases, but not ERKs, induced by UV radiation. Taken together with the evidence that MAPK signaling pathways play important roles in UV-induced AP-1 activation (50–52) and p53 functions as a main tumor suppressor, these results indicate that inhibitory effect of p53 on AP-1 activation may be due to its specific inhibition of the p38 kinase and JNK pathways, but not the ERK pathway.

The activation of Akt depends on phosphorylation of four sites, including Ser124, Thr450, Thr308, and Ser473 (53). Mutagenesis studies have suggested that phosphorylation of Thr308 and Ser473 is required for Akt activity, whereas Ser124 and Thr450 seem to be basally phosphorylated (53). The activation of p70S6k is attributable to phosphorylation of Ser/Thr residues on multiple sites, such as Thr389, Ser424, and Thr421 (54). Upon activation, p70S6k phosphorylates the S6 protein of the 40S ribosomal subunit, resulting in increase of the production of translational machinery components, such as ribosomal proteins and elongation factors (54). Previous studies have shown that the activation of PI-3K/Akt/p70S6k pathways is required for AP-1 activation in cell responses to growth factors and oxidative stress (36, 55). In the present study, we found that inhibition or knockout of p53 resulted in a dramatic increase in the UV-induced phosphorylation of Akt at Ser473 and Thr308, and p70S6k at Thr389 and Thr421/Ser424, suggesting that suppression of AP-1 activation by normal p53 could be mediated by targeting Akt/p70S6k pathway.

PTEN is an important tumor suppressor frequently mutated in human cancers and is a negative regulator of PI-3K/Akt–dependent cell survival (14, 56). Despite a relatively good understanding of the molecular roles of PTEN in the control of cellular functions, little is known about mechanisms of PTEN regulation. Recently, a functional p53 binding site was identified within the pten promoter (38). This DNA sequence was required for p53-mediated inducible PTEN expression, whereas basal levels of PTEN transcription are controlled by the element outside of the p53-responsive region within the PTEN promoter (38). Furthermore, p53 induction in DP16 erythroleukemia cells resulted in reduction of Akt phosphorylation (38), revealing a mechanism for the direct involvement of p53 in negative regulation of cellular survival via activation of PTEN transcription. In this study, we found that p53 deficiency resulted in a dramatic decrease in PTEN expression in embryonic fibroblast cells. Considering that p53 deficiency also enhanced activation of Akt and p70S6k in the same cells, and PTEN functions as an inhibitor of PI-3K/Akt pathway, we anticipate that p53 may inhibit UV-induced activation of Akt and p70S6k by down-regulating the PTEN expression. In addition, our previous studies showed that Akt can act as the upstream signal of MAPKs in B(a)PDE- and 5-methylacrysene-1,2-diol-3,4-epoxide–triggered signal cascades (30, 57). Here, we found that both overexpression of PTEN and MAPK inhibitors can inhibit p53-deficiency–induced elevation of AP-1 activation, suggesting that Akt may also be the upstream of MAPKs in UV response.

In summary, the present study indicated that p53 has an inhibitory effect on basal level and UV-induced level of AP-1 and NF-{kappa}B activities through specifically suppressing the p38 kinase and JNK pathways, but not the ERK pathway. The UV-induced activation of Akt and p70S6k could also be inhibited by normal p53 function. These findings show that p53 has a suppressive function in the cellular signaling pathways, which are thought to be essential for UV-induced carcinogenesis. Because p53 deficiency resulted in a dramatic decrease in expression of PTEN, a tumor suppressor and negative regulator of PI-3K/Akt pathway, taken together with the evidence that PI-3K/Akt participates in the activation of AP-1 and NF-{kappa}B, we anticipate that normal p53 may up-regulate PTEN protein expression, and PTEN expression leads to inhibition of PI-3K/Akt pathway, which may subsequently result in inhibition of AP-1 and NF-{kappa}B. This seems to be a potential novel mechanism involved in anticancer activity of p53 protein.


   Acknowledgments
 
Grant support: NIH/National Cancer Institute grant R01 CA094964 and R01 CA112557; NIH/National Institute of Environmental Health Sciences grant R01 ES012451; and The Special Funds for Major State Basic Research Program of China, National Natural Science Foundation of China, and the Commission of Science and Technology, Shanghai Municipality (L. Wei).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Deepti S. Wilkinson (Department of Biochemistry and Molecular Biology, University of Texas, MD Anderson Cancer Center, Houston, TX) and Dr. Michelle Craig Barton for the gift of p53 siRNA construct and Dr. Xia Zhang for the gift of EGFP-PTEN fusion protein expression vector.


   Footnotes
 
Note: J. Wang, W. Ouyang, J. Li, and L. Wei contributed equally to this work. J. Wang is currently in the Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032 Shannxi, China.

Received 11/22/04. Revised 4/14/05. Accepted 5/27/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Pathak MA. Ultraviolet radiation and the development of non-melanoma and melanoma skin cancer: clinical and experimental evidence. Skin Pharmacol 1991;4 Suppl1:85–94.
  2. Gervin CM, McCulla A, Williams M, Ouhtit A. Dysfunction of p53 in photo-carcinogenesis. Front Biosci 2003;8:s715–7.[Medline]
  3. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML. p53 protects against skin cancer induction by UV-B radiation. Oncogene 1999;8:4247–53.
  4. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774–83.[CrossRef][Medline]
  5. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247–54.[CrossRef][Medline]
  6. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644–55.[CrossRef][Medline]
  7. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–31.[CrossRef][Medline]
  8. Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995;5:84–90.[CrossRef][Medline]
  9. Huang C, Ma WY, Li J, Hecht SS, Dong Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res 1998;58:4102–6.[Abstract/Free Full Text]
  10. Meek DW, Campbell LE, Jardine LJ, Knippschild U, McKendrick L, Milne DM. Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Biochem Soc Trans 1997;25:416–9.[Medline]
  11. Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 1998;8:325–36.[CrossRef][Medline]
  12. Soddu S, Sacchi A. P53 role in DNA repair and tumorigenesis. J Exp Clin Cancer Res 1997;16:237–42.[Medline]
  13. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030–40.[CrossRef][Medline]
  14. Maehama T, Dixon J. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375–8.[Abstract/Free Full Text]
  15. Davies M, Koul D, Dhesi H, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999;59:2551–6.[Abstract/Free Full Text]
  16. Furnari F, Huang H, Cavenee W. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58:5002–8.[Abstract/Free Full Text]
  17. Stambolic V, Suzuki A, de la Pompa J, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29–39.[CrossRef][Medline]
  18. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada K. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614–7.[Abstract/Free Full Text]
  19. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000;1470:M21–35.[Medline]
  20. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237–42.[Abstract/Free Full Text]
  21. Huang C, Huang Y, Li J, et al. Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor {kappa}B by black raspberry extracts. Cancer Res 2002;62:6857–63.[Abstract/Free Full Text]
  22. Wilkinson DS, Ogden SK, Stratton SA, et al. A direct intersection between p53 and transforming growth factor ß pathways targets chromatin modification and transcription repression of the {alpha}-fetoprotein gene. Mol Cell Biol 2005;25:1200–12.[Abstract/Free Full Text]
  23. Ning K, Pei L, Liao M, et al. Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J Neurosci 2004;24:4052–60.[Abstract/Free Full Text]
  24. Huang C, Ma W-Y, Ryan CA, Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV-induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc Natl Acad Sci U S A 1997;94:1957–62.
  25. Huang C, Ma W-Y, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Cancer Res 1997;57:2873–8.[Abstract/Free Full Text]
  26. Li J, Chen H, Ke Q, et al. Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NF-{kappa}B in mouse epidermal Cl41 cells. Mol Carcinog 2004;40:104–15.[CrossRef][Medline]
  27. Zhang Z, Chen F, Huang C, Shi X. Vanadate induces G2/M phase arrest in p53-deficient mouse embryo fibroblasts. J Environ Pathol Toxicol Oncol 2002;21:223–31.[Medline]
  28. Zhang Z, Huang C, Li J, Shi X. Vanadate-induced cell growth arrest is p53-dependent through activation of p21 in C141 cells. J Inorg Biochem 2002;89:142–8.[Medline]
  29. Huang C, Li J, Ding M, et al. Arsenic-induced NF{kappa}B transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001;222:29–34.[CrossRef][Medline]
  30. Li J, Tang MS, Liu B, Shi X, Huang C. A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl 41 cells. Oncogene 2004;23:3932–44.[CrossRef][Medline]
  31. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor {kappa}B (NF-{kappa}B)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000;28:1338–48.[CrossRef][Medline]
  32. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733–7.[Abstract/Free Full Text]
  33. Murphy PJ, Galigniana MD, Morishima Y, et al. Pifithrin-{alpha} inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 2004;279:30195–201.[Abstract/Free Full Text]
  34. Zhang M, Liu W, Ding D, Salvi R. Pifithrin-{alpha} suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003;120:191–205.[CrossRef][Medline]
  35. Komarova EA, Neznanov N, Komarov PG, Chernov MV, Wang K, Gudkov AV. p53 inhibitor pifithrin {alpha} can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem 2003;278:5465–8.
  36. Huang C, Li J, Ke Q, et al. Ultraviolet-induced phosphorylation of p70S6K at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res 2002;62:5689–97.[Abstract/Free Full Text]
  37. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241–8.[Abstract/Free Full Text]
  38. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001;8:317–25.[CrossRef][Medline]
  39. Stratton MR. The p53 gene in human cancer. Eur J Cancer 1992;28:293–5.
  40. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 2004;3:156–61.[Medline]
  41. Appella E. Modulation of p53 function in cellular regulation. Eur J Biochem 2001;268:2763.[Medline]
  42. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002;12:60–6.[CrossRef][Medline]
  43. Huang C, Ma WY, Maxiner A, Sun Y, Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 1999;274:12229–35.[Abstract/Free Full Text]
  44. Reid T, Jin X, Song H, Tang HJ, Reynolds RK, Lin J. Modulation of Janus kinase 2 by p53 in ovarian cancer cells. Biochem Biophys Res Commun 2004;321:441–7.[CrossRef][Medline]
  45. Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A 2001;98:5025–30.[Abstract/Free Full Text]
  46. Dhar A, Young MR, Colburn NH. The role of AP-1, NF-{kappa}B and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 2002;234–235:185–93.
  47. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor {kappa}B (NF-{kappa}B)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000;28:1338–48.
  48. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003;2003:RE2.
  49. Nakade K, Zheng H, Ganguli G, Buchwalter G, Gross C, Wasylyk B. The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling. Mol Cell Biol 2004;24:1132–42.[Abstract/Free Full Text]
  50. Huang C, Li J, Chen N, Ma W, Bowden GT, Dong Z. Inhibition of atypical PKC blocks ultraviolet-induced AP-1 activation by specifically inhibiting ERKs activation. Mol Carcinog 2000;27:65–75.[CrossRef][Medline]
  51. Chen W, Bowden GT. Role of p38 mitogen-activated protein kinases in ultraviolet-B irradiation-induced activator protein 1 activation in human keratinocytes. Mol Carcinog 2000;28:196–202.[CrossRef][Medline]
  52. Ma WY, Huang C, Dong Z. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase. Int J Oncol 1998;12:565–8.[Medline]
  53. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003;546:108–12.[CrossRef][Medline]
  54. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997;410:78–82.[CrossRef][Medline]
  55. Huang C, Ma WY, Dong Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol Cell Biol 1996;16:6427–35.[Abstract]
  56. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171–6.[CrossRef][Medline]
  57. Li J, Chen H, Tang MS, et al. PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl 41 cells. J Cell Biol 2004;165:77–86.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Han, J. D. Ritzenthaler, Y. Zheng, and J. Roman
PPAR{beta}/{delta} agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-{kappa}B signals
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1238 - L1249.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. Yao, C. L. Alexander, J. A. Quinn, W.-C. Chan, H. Wu, and D. A. Greenhalgh
Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21WAF-induced differentiation triggered by GSK3{beta} inactivation and reduced AKT activity
J. Cell Sci., May 15, 2008; 121(10): 1758 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Luo, J. Liu, J. Li, D. Zhang, M. Liu, J. K. Addo, S. Patil, L. Zhang, J. Yu, J. K. Buolamwini, et al.
Anti-cancer Effects of JKA97 Are Associated with Its Induction of Cell Apoptosis via a Bax-dependent and p53-independent Pathway
J. Biol. Chem., March 28, 2008; 283(13): 8624 - 8633.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
D. Zhang, J. Li, L. Song, W. Ouyang, J. Gao, and C. Huang
A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression
Mol. Cancer Res., January 1, 2008; 6(1): 165 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
T. Tamguney and D. Stokoe
New insights into PTEN
J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Groskreutz, M. M. Monick, T. O. Yarovinsky, L. S. Powers, D. E. Quelle, S. M. Varga, D. C. Look, and G. W. Hunninghake
Respiratory Syncytial Virus Decreases p53 Protein to Prolong Survival of Airway Epithelial Cells
J. Immunol., September 1, 2007; 179(5): 2741 - 2747.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero
PTEN, more than the AKT pathway
Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. Song, J. Li, J. Ye, G. Yu, J. Ding, D. Zhang, W. Ouyang, Z. Dong, S. O. Kim, and C. Huang
p85{alpha} Acts as a Novel Signal Transducer for Mediation of Cellular Apoptotic Response to UV Radiation
Mol. Cell. Biol., April 1, 2007; 27(7): 2713 - 2731.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Zhang, L. Song, J. Li, K. Wu, and C. Huang
Coordination of JNK1 and JNK2 Is Critical for GADD45{alpha} Induction and Its Mediated Cell Apoptosis in Arsenite Responses
J. Biol. Chem., November 10, 2006; 281(45): 34113 - 34123.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tang and C. Eng
p53 Down-Regulates Phosphatase and Tensin Homologue Deleted on Chromosome 10 Protein Stability Partially through Caspase-Mediated Degradation in Cells with Proteasome Dysfunction.
Cancer Res., June 15, 2006; 66(12): 6139 - 6148.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, J.
Right arrow Articles by Huang, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, J.
Right arrow Articles by Huang, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online